Dogwood Therapeutics, Inc. • DWTX

Capital at risk.

About Dogwood Therapeutics, Inc.
Ticker
info
DWTX
Trading on
info
NASDAQ
ISIN
info
US92829J2033
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Gregory Duncan
Headquarters
info
44 Milton Avenue, Alpharetta, GA, United States, 30009
Employees
info
12
Website
info
https://dwtx.com
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Metrics
BasicAdvanced
Market cap
info
$89.2M
P/E ratio
info
-
EPS
info
-$25.59
Dividend Yield
info
0.00%
Beta
info
1.92
Forward P/E ratio
info
0
EBIDTA
info
-
Ex dividend date
info
-
Price & volume
Market cap
info
$89.2M
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
1.35
Earnings
EPS
info
-$25.59
EPS estimate (current quarter)
info
-$1.58
EPS estimate (next quarter)
info
-$1.17
EBITDA
info
-
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
1.92
52-week High
info
$29.28
52-week Low
info
$2.05
50-day moving average
info
$5.19
200-day moving average
info
$5.13
Short ratio
info
1.42
Short %
info
0.28%
Management effectiveness
ROE (TTM)
info
-930.96%
ROA (TTM)
info
-42.04%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
29.7M
Float
info
0.5M
Insiders %
info
84.27%
Institutions %
info
0.37%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 2 analysts.

Average price target

info
$19.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$6.29
-$0.06
-10,993.47%
Q4 • 24Missed
-$8.45
-$0.77
-1,004.63%
Q1 • 25Missed
-$9.51
-$0.05
-18,920.00%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-3.8M
-∞%
Q2 • 25
$0M
$-15.7M
-∞%
Q3 • 25
NaN%
313.53%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$96.7M
$14.2M
14.64%
Q2 • 25
$92M
$14.6M
15.88%
Q3 • 25
-4.86%
3.22%
8.49%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-4M
-
$-0.1M
$-4M
Q2 • 25
$-3.3M
-
$0M
$-3.3M
Q3 • 25
-18.71%
-
-100.00%
-18.71%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Dogwood Therapeutics, Inc. share?
Collapse

Dogwood Therapeutics, Inc. shares are currently traded for undefined per share.

How many shares does Dogwood Therapeutics, Inc. have?
Collapse

Dogwood Therapeutics, Inc. currently has 29.7M shares.

Does Dogwood Therapeutics, Inc. pay dividends?
Collapse

No, Dogwood Therapeutics, Inc. doesn't pay dividends.

What is Dogwood Therapeutics, Inc. 52 week high?
Collapse

Dogwood Therapeutics, Inc. 52 week high is $29.28.

What is Dogwood Therapeutics, Inc. 52 week low?
Collapse

Dogwood Therapeutics, Inc. 52 week low is $2.05.

What is the 200-day moving average of Dogwood Therapeutics, Inc.?
Collapse

Dogwood Therapeutics, Inc. 200-day moving average is $5.13.

Who is Dogwood Therapeutics, Inc. CEO?
Collapse

The CEO of Dogwood Therapeutics, Inc. is Gregory Duncan.

How many employees Dogwood Therapeutics, Inc. has?
Collapse

Dogwood Therapeutics, Inc. has 12 employees.

What is the market cap of Dogwood Therapeutics, Inc.?
Collapse

The market cap of Dogwood Therapeutics, Inc. is $89.2M.

What is the P/E of Dogwood Therapeutics, Inc.?
Collapse

The current P/E of Dogwood Therapeutics, Inc. is null.

What is the EPS of Dogwood Therapeutics, Inc.?
Collapse

The EPS of Dogwood Therapeutics, Inc. is -$25.59.

What is the PEG Ratio of Dogwood Therapeutics, Inc.?
Collapse

The PEG Ratio of Dogwood Therapeutics, Inc. is null.

What do analysts say about Dogwood Therapeutics, Inc.?
Collapse

According to the analysts Dogwood Therapeutics, Inc. is considered a buy.